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ABSTRACT 
Photodynamic therapy (PDT) is a treatment for a wide display of diseases, including 
cancer, that has become gradually widespread. The procedure requires the usage of 
photosynthesizing agents, which are activated in the presence of light. One quite successful 
photodynamic therapy agent is an aromatic structure made up of four pyrrole rings called a 
porphyrin. This research focused on producing the water-soluble porphyrins, H2TPP-3-PEG-OH 
and H2TPP-PiperMe-OH, through the attachment of the starting porphyrin, H2TPPC, with  
3-polyethyleneglycol and 3-piperidinemethanol, respectively. The novel, water-soluble agent 
was purified and characterized by infrared spectroscopy (IR), nuclear magnetic resonance 
spectroscopy (NMR), and UV-vis spectroscopy. Purity was determined using high performance 
liquid chromatography (HPLC). To find the cytotoxicity level of novel PDT porphyrins, H2TPP-
3-PEG-OG and H2TPP-3-PiperMe-OH, the agents were conditionally tested in the presence and 
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BACKGROUND 
 According to the National Cancer Institute, roughly 25% of the US population will 
develop cancer at some point within their lifespan. [4,21] Annually, billions of dollars across the 
globe are spent on cancer research, to cure or to improve treatment options for such a diagnosis. 
As of today, the primary treatment for cancer is typically surgical and is paired with radiation 
and/or chemotherapy. This course of action, however, especially when chemotherapy is the 
treatment option, has major and broad side effects for the patient. All rapidly dividing tissues are 
affected, which leads to a loss of hair, extreme loss of appetite, painful digestion, severe anemia, 
and skin sensitivity. Due to the side effects, the dosage that can be administered during treatment 
is limited and reduces the patient’s quality of life substantially. Using chemotherapy, in 
combination with surgery and radiation, as a treatment for cancer, is dangerous. Sensing the need 
for a more target-specific treatment in relation to cancer, researchers began the development of 
Photodynamic Therapy (PDT). 
 
How Photodynamic Therapy Works 
In PDT, an agent, or photosensitizer, is used in combination with a light source to make 
tissue light-sensitive, thereby killing cancerous cells. [1] It functions by allowing a physician to 
inject a PDT agent, which is non-toxic until exposed to specific wavelengths of light, into the 
affected area. Both healthy and malignant cells throughout the body absorb the PDT agent. 
Compared to normal cells, malignant cells take in greater amounts of the agent. [3] After an 
incubation period, from minutes to a couple of days, the agent dissipates from healthy cells and 
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remains in malignant ones. [22] It is still currently being investigated, as to why the malignant 
cells retain the drug for a longer period.  
The physician then directs light at the target tissue, via a laser, UV light, or other light 
source, which is now light-sensitive due to the PDT agent. Upon exposure to the chosen 
wavelength, the PDT agent produces a singlet, reactive oxygen species, or an oxygen  
free-radical, that can destroy cancer cells. The product is believed to treat the cancer by 
damaging the tumor’s blood cells, aiding the body’s own immune system in attacking the 






In part a, light and a photosensitizer is being combined to produce a photochemical 
effect, which triggers tumor necrosis. In part b, the PDT agent is administered, and an 
incubation period is allotted to allow for accumulation of the drug within the 
malignant cells. Then, the affected area is treated with a light source and  
the physician uses a camera to assess the tumor and determine  
if the treatment was effective.  
(http://sites.dartmouth.edu/pdt/)  
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How PDT Came to Be 
PDT, in a modern sense, is a new, evolving science, but the idea of it is almost ancient. 
After careful examination of ancient German, Danish, and French texts, one sees light used for 
medicinal purposes that can be traced from antiquity to present day. [26] Light first began as a 
therapeutic agent in the Egyptian, Indian, and Chinese peoples. Their cultures used light to treat 
vitiligo, rickets, psoriasis, skin cancer, and psychosis. [24,25] 3000 years ago, the Greeks spoke 
highly of heliotherapy, or total body exposure to the sun. Herodotus, a renowned physician in 2nd 
century BC and the father of heliotherapy, stressed the importance of the sun in the restoration of 
one’s health. These practices and beliefs were forgotten though and were eventually regarded as 
pagan practices, as Christianity became the primary religion throughout the world.  
However, in 1815, the thought of using light as a medicinal tool was rediscovered. A 
physician by the name of Cauvin re-established our perception of the sun’s benefits, as he 
noticed it was an effective therapy for rickets. From this point, research in phototherapy took off 
and it developed into a science. Niels Finsen, a Danish physician, popularized phototherapy 
when his work in the field won a Nobel prize in 1903. [26]  
Light research also looked at the combination of light and photosensitizers through the 
field of photochemotherapy. Individuals used exogeneous sensitizers to absorb photons with the 
intention of a reaction for a therapeutic effect. [26] The photosensitizers, or porsalens, were used 
in India as early as 1400 BC and by Egyptians around 12th century AD. These peoples used 
porsalens obtained from various plants combined with natural ultraviolet light to treat skin 
conditions, such as vitiligo and psoriasis. [2] At the beginning of the 20th century, Oscar Raab, a 
medical student, examined photosensitized reactions in specific ways and ultimately introduced 
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the subject to western medicine. [27] He hypothesized that there was a transfer of light energy to 
chemical energy, but his explanation of the science was incomplete due to the limited 
understanding of fluorescence at the time. In order to address this issue, his teacher, Professor 
Herman von Tappeiner and Dermatologist Jesionek, took over Raab’s research and developed a 
clinical study. [28] They set out to determine if eosin could be used as a photosensitizer in the 
treatment of skin cancer, lesions of the skin, and chondylomata of female genitalia. In 1904, they 
reported that oxygen was required for an affected area to become photosensitized and three years 
later, von Tappeiner compiled the experiments into a book, coining the term ‘Photodynamic 
Therapy’. [29] His predictions for the applications of photosensitizers and his push for the use of 
phototherapy for tumors, make von Tappeiner one of the most important early pioneers for the 
field of PDT.   
 
Are there Advantages or Limitations to Using PDT as a Treatment?  
With more and more findings in the field of photodynamic therapy, many physicians are 
suggesting PDT as a viable treatment option that could one day work as well as standard 
treatments, like chemotherapy or surgery. [16,19] Of course, both physician and patient must keep 
in mind that medicine is never a “one size fits all” situation and some treatments might work 
better for one individual, while not at all for the next. [30]  
Physicians promote PDT because of its benefits for the patient. Due to this treatment 
option, physicians have more control and may eventually be able to selectively destroy malignant 
cells, sparing all healthy tissues. [20]  
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There are, however, advantages and limitations to PDT. One benefit to PDT is, while 
every procedure has some risk, the risks associated with PDT are quite minimal and much less 
dangerous than surgery. The therapy can also be applied in regions of the body where surgery 
may not be an option and may be repeated many times in the affected area if the first treatment is 
unsuccessful, unlike radiation therapy. [22] PDT is also a much safer option due to its minimally 
invasive nature, especially for patients considered too high a risk to undergo chemotherapy, 
radiation, or surgery. These patients consist of the elderly, those vulnerable to surgery, those with 
immunological disorders, etc.[20] PDT has fewer adverse effects, shorter treatment time, and is 
usable in outpatient settings, which make it a prime treatment option for patients who are 
considered high risk or for those who wish to make the treatment experience as good as possible 
without reduction of quality of life. [19] PDT also leaves little to no scarring post healing process 
and typically has a lower cost than other treatment options. [12, 18] 
While, physicians say that while PDT is a good option, patients should still understand 
that there are side effects, like every therapy. [10] After treatment, it is common for patients to 
experience photosensitivity, or sensitivity to light due to the medication given. These symptoms 
may include unexpected sunburns or dermatitis on skin exposed to the sun. The medication can 
also cause onycholysis (FIGURE 2), or the lifting of the nail plate from the nail bed. [6,7] To help 
decrease side effects, physicians recommend keeping shades and curtains on windows, wearing 
clothing to cover as much skin as possible, or walking with a darker umbrella, and making sure 
to not rely on sunscreen for at least one-month post-treatment, as it will not prevent any reactions 
the one might have. [18]  






As it is a new treatment modality and still in development, PDT also has limitations. The 
treatment’s effectiveness largely depends upon how accurately light is being delivered to the 
tumor or affected site. Tumors that are too deep for visible light to penetrate have proven to be 
difficult to treat, as they are not accessible without surgical intervention. For now, PDT only has 
the ability to target cells within 1/3 of an inch of the light source. [18] Oxygenation of the tumor 
and surrounding tissue is also important for PDT. A patient who has a tumor surrounded by 
necrotic tissue will have a limited photodynamic therapy treatment. Without oxygen, free-
radicals, which kill the cancerous cells, are not produced. PDT is also limited to specific sites; 
therefore, the PDT effect only takes place at an irradiated site. With the current available 
technology, treating metastases or performing whole body radiation with PDT is not available. 
[19] Since it functions by targeting tumors, PDT cannot treat cancer that have spread throughout 
the body, nor can it treat diseases, such as leukemia (FIGURE 2). [16]  
FIGURE 2: 
On the left is a photo of onycholysis, or the lifting of the nail plate from the  
nail bed. The image to the right shows what leukemia, a blood cancer, does to the 
body. There is a rapid increase of immature blood cells and due to the 
overcrowding, healthy blood cells cannot be produced.  
(http://biyaninursingcollege.com/what-is-leukemia-its-type-etiology-classificationsign-
symptomdiagnostic-findings-treatment/ (right); https://www.researchgate.net/figure/Onycholysis-
semilunaris-A-is-characterized-by-its-half-moon-shape-and-clear-border_fig19_221924704 (left))  
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What Types of Treatments is PDT Used For?  
However, despite its limitations, physicians still developed ways to use the treatment. As 
PDT has grown, researchers have increased their support its use for uses aside from just 












Katie, a 21-year-old who suffered from anaplastic ependymoma, or an aggressive form of 
brain cancer, says that she had seven brain surgeries before Dr. Harry Whelan, a neurologist, 
suggested PDT. [5] After three aggressive treatments, the tumors have not rematerialized on 
Katie’s brain. PDT is also being used for esophageal cancers, which affects around 12,000 
Americans every year. [14] To save Francis’ life, the doctor would have had to remove a large 
FIGURE 3: 
Jane underwent PDT for her acne. This is the result after 3 treatments.  
(https://www.skinmdandbeyond.com/faq-face-photodynamic-therapy/)  
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portion of the esophagus, leaving Francis to eat through a feeding tube for the remainder of his 
life. After his PDT treatment, he reported to Current Science Magazine, “I can eat anything I 
want.” [5] For now, especially in the US, PDT is only approved for patients that have no other 
alternatives and are diagnosed with late-stage esophageal cancer or early-stage lung cancer. [16] 
A new field of PDT is also being explored: photoangioplasty. This treatment uses the 
photosensitizer to break up the plaque build up in blood vessels, so the patients’ arteries are no 
longer clogged. This process is illustrated in FIGURE 4 and FIGURE 5 below. Doctors are 
hoping that these studies will one day offer new options to patients suffering from ischemia, or a 
disease causing an inadequate blood supply to an organ or other part of the body, especially the 
heart muscles. [17] 




An Illustrated example of a blocked artery due to plaque buildup, that would typically 
be solved using more invasive means outside of PDT. Now, the issue can be solved 
with a photoangioplasty.  
(https://metrohealth.net/healthwise/coronary-angioplasty/) 
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Currently, verteporfin, a photosensitizing drug licensed for PDT, is used in the treatment 
of age-related macular degeneration (AMD) and pathological myopia. [2] These diseases result in 
damage to the macula, a central area of the retina. AMD also occurs when blood vessels in the 
eyes begin to leak, causing scar tissue build-up in the light sensitive portion of the eye. While 
PDT cannot remove scar tissue already present, it does stop the disease from progressing. [14] 
FIGURE 6 shows how PDT functions within the eye and FIGURE 7 shows the treatment 
illustrated and being used on a woman diagnosed with AMD. 
                     
FIGURE 5: 
An imaging, or real-life, example of a blocked artery due to plaque buildup, 
that would typically be solved using more invasive means outside of PDT. 
Now, the issue can be solved with a photoangioplasty.  
(https://metrohealth.net/healthwise/coronary-angioplasty/) 
 



















PDT can treat AMD by stopping the 
leakage of abnormal retinal tissue in the 
back of the eye. The procedure calls for a 
photosensitizing dye to be injected into the 
patient’s arm, which is then absorbed by 
structures in the eye. The photosensitizer is 
then activated by the laser. Abnormal blood 
vessels are selectively treated without 






The image on the left, is an illustrated example of how the laser penetrates the eye during an AMD PDT 
treatment. The photo on the right is of a woman undergoing the treatment.   
(https://retinamaculainstitute.com/photodynamic-therapy/) 
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How is Optimal PDT Achieved?  
To help combat the limitations of PDT and aid in new research, scientists from all over 
the world have been working to improve light dosimetry and develop new photosensitizers, both 
key components in PDT.  
As the depth of the tissue penetration is affected by the light’s wavelength, scientists 
began their research by looking into the science behind light dosimetry. The most frequent light 
source used today is a laser, but other sources include, intense pulsed light, light-emitting diodes 
(LEDs), and light of various colors, like blue, red, and natural sunlight. Researchers found that 
skin treatments typically require the light source to be directly shown on the skin for an 
appropriate amount of time and light for internal cancers, in the bladder, lungs, stomach or 
esophagus, can be delivered by means of small, fiber-optic cables. [18] By using wavelengths of 
600 to 800 nm, researchers have found that light delivery can be enhanced. [8,9,19]  
To have an ideal photosensitizer, it must be able to produce the singlet oxygen necessary 
for the degradation of tumors. [13] It should have a highly absorbent coefficient, or the ability to 
absorb light at a particular wavelength. [20] During testing, the photosensitizer should not accrue 
toxicity in the dark and should selectively congregate in the cancerous cells. There should only 
be cytotoxicity in the presence of light. [13] Also, in a clinical trial, the photosensitizer must be 
chemically pure, stable, and produce minimal skin toxicity. [20] With these characteristics in 
mind, scientists began to develop photosensitizers with the end goal that they would one day be 
used to help cure cancer. 
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The Development of Porphyrins as PDT Agents 
After the development and FDA approval of Photofrin, a hematophorphyrin derivative 
and the first photosensitizer for PDT, the therapy option has been accepted “for treating various 
forms of cancer in many countries…and is also being tested as a possible therapeutic agent 
against abdominal and thoracic cancers, brain, breast, and skin.” [11,13,30] Other porphyrin 
derivatives have also been approved for clinical use: Visudyne, Temoporfin, and Talaporfin. 
These FDA approvals have led to significant PDT research using both natural and synthetic 
porphyrins.  
Recently, researchers have concentrated on using porphyrins as the photosensitizer, due 
to its unique properties of a multiring structure, its presence in biological systems, and its 
photosensitizing abilities. After its detection in 1897, the molecule has been applied in various 
fashions, such as gene regulation, hormone synthesis, and as a solar cell.  
In the words of Igor Stojiljkovic, et. al, [15] “Prophyrins are the most colorful and 
probably most widespread enzyme co-factors in nature.” The porphyrin molecule is a 















The most recognizable structure that contains a porphyrin macrocycle is hemoglobin  
in red blood cells. Characteristics of a porphyrin include a dark purple, photosensitive pigment  











The structure of a porphyrin molecule, with molecular formula C20H14N4. 
(https://en.wikipedia.org/wiki/Porphine) 
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RESEARCH  
MATERIALS & METHODS 
Porphyrin Synthesis 
This research utilizes the light absorbing characteristic of porphyrins, which allow the 
molecule to be activated by photons and results in a desired reaction with the targeted cells. The 
goal was to create two, novel PDT agents that were water-soluble and contain typical porphyrin 
characteristics. The two amines used to create the porphyrins in this investigation are amino-
PEG-3-alcohol and 3-piperidinemethanol. 
  
 
 Water solubility was a critical factor in this project as the main goal was to make a 
porphyrin with the intention that it could one day be used in vivo, meaning within a living 
organism. A physician administers PDT agents to a patient through skin application or injection 
to the affected area. As the body consists of roughly of 60% water and the blood has a 
concentration of water approximately 92%, it is important that the agent is water-soluble. This 
ensures successful entry into the cells and allows the drug to accumulate where it is needed.  
 
FIGURE 10: 
The structure of 3-Piperidinemethanol  
(3.79 X 10-3 mol, MW = 115.18) 
FIGURE 9: 
The structure of Amino-PEG-3-Alcohol.  
(1.67 X 10-3 mol, MW = 149.2) 
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Synthesis of H2TPPC 
With the goal of attaching the amines to the porphyrin structure and making the new 
agent water-soluble, first H2TPPC, the starting material, was synthesized. The experiment began 
by adding 3 g of 4-formylbenzoic acid and a stir bar to a clean, dry 500 ml round bottom flask. 
The flask was then placed on a heating mantle and 250 ml of propionic acid was added. Then, 
Gloves were appropriated for protection against the harsh chemicals when adding 1.5 ml of 
pyrrole via syringe. The solution was refluxed for 1 hour and the entire apparatus was wrapped 
in aluminum foil to protect it from light. After an hour, the flask and its contents were left to 
cool. Then, the flask was wrapped in aluminum foil, parafilm was placed across the top, and the 
flask was labeled. The flask was then placed in a freezer overnight.  
The product should then be filtered using a medium sintered glass filter and washed with 
roughly 30 ml of dichloromethane. Washing was repeated until no product remained in the flask. 
The M glass filter with the final product (it should be a purple/black color) was left to dry 
overnight. 
 
Synthesis of H2TPP-3-PEG-OH 
 Once the starting material was synthesized, the acid chloride had to made, so the amino-
PEG-3-alcohol could be attached to the porphyrin structure itself. All required glassware was 
dried in the oven overnight. The reaction is air sensitive, and its environment must stay dry at all 
times. The reaction began by weighting out 0.13 g of H2TPPC, adding it to a 50ml round bottom 
flask, and placing the flask under a nitrogen sparge. Then, 10 ml of Dimethylformamide (DMF) 
and a stir bar was added to the flask. 0.15 ml of thionyl chloride (SOCl2) was then added via 
syringe. The reaction was allowed to sit and stir for 1 hour. The product, H2TPPCl, was green. 
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After an hour, the flask was disconnected from the nitrogen sparge and connected to the 
rotary evaporator (rotovap), as seen in FIGURE 11, using KECK clips. The Rotovap’s purpose 
was to eradicate chemicals that contain lower boiling points from a mixture, while isolating the 
desired product. The mixture was evaporated to dryness. After evaporation of the DMF, the dried 
product was be a shimmery blue-green color. The product was kept under vacuum overnight. 
   









Next, methanol was distilled so it could be used in the final step of the porphyrin 
synthesis. The flask was removed from vacuum and placed under a nitrogen sparge. After 
retrieving a small, clean glass vial, 0.25 g of amino-PEG-3-alcohol was added and then dissolved 
in 25ml of freshly distilled methanol. The reaction was allowed to stir under nitrogen for 1 hour. 
After an hour, the solution was rotovapped to dryness, evaporating all traces of methanol. The 
FIGURE 11: 
This is a photograph of a Rotovap. Glassware 
is connected to the machine using KECK clips 
(green adapters). All unwanted solvents are 
removed via vacuum, are trapped in the 
condenser, and are collected in the larger flask 
for later disposal. It utilizes a hot water bath to 
prevent the mixture from freezing during 
evaporation. 
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final product was be a deep purple color, as seen in FIGURE 12. This product was named 
H2TPPC-3-PEG-OH. Next, the product was purified using column chromatography.  
       
 
Synthesis of H2TPP-3-PiperMe-OH 
The porphyrin synthesis was repeated using a second amine, 3-piperidinemethanol. 
However, the acid chloride reaction began with 0.25 g of H2TPPC and 0.25ml of thionyl 
chloride. The remaining synthesis was identical to that of H2TPP-3-PEG-OH, with the 
substitution of 0.437 g of 3-piperidinemethanl for animo-PEG-3-alcohol in the final reaction. 
This product was named H2TPPC-3-PiperMe-OH. Next, the product was purified using column 
chromatography.  
FIGURE 12: 
These are photographs of the final porphyrin product. Notice the color is 
purple, a characteristic of a porphyrin.  
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Summary of Porphyrin Synthesis 






In step 1, 4-formylbenzoic acid (2) was reacted with pyrrole (1) in propionic 
acid forming H2TPPC (3) 
 
FIGURE 14: 
In step 2, H2TPPC (3) was reacted with SOCl2 in DMF to form 
 Acid Chloride (4), or H2TPPCl. 
 
 








Finally, in step 3 A, the acid chloride (4), or H2TPPCl, was reacted with the 
amine, amino-PEG-3-alcohol, in methanol to form the  
final product, H2TPP-3-PEG-OH. 
FIGURE 15B: 
Finally, in step 3 B, the acid chloride (4), or H2TPPCl, was reacted with the 
amine, 3-piperidinemethanol, in methanol to form the  
final product, H2TPP-3-PiperMe-OH. 
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Purification of the Porphyrin Products 
Low pressure liquid column chromatography was used for the porphyrin purification. 
This type of chromatography was used to separate proteins, nucleic acids, or small molecules in 
complex mixtures. It uses a liquid phase, which is mobile, and a solid phase, which is stationary. 
The desired molecules in the mobile phase are separated based on their differing physiochemical 
interactions with both the stationary and mobile phases. [32] 
Low pressure liquid column chromatography was prepared by setting up a glass column 
with pressurized air at the top of the apparatus, as seen in FIGURE 16. The column material, or 
slurry, was prepared 24-hours in advance by mixing LH-20 with 50:50 MeOH- H2O, or G-50 
with Milli-Q H2O, so that the material could hydrate under the added eluent.  











The photo above shows an example of low pressure liquid column chromatography. Notice the air 
apparatus at the top of the glass column (seen in photo on left), the product being filtered through the 
LH-20 column material, and the collection of the product at the bottom in an Erlenmeyer flask.  
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Each porphyrin was purified separately by first passing it through 0.45mm nylon syringe 
filters and then through Sephadex LH-20 using a 50:50 methanol/water mixture as the eluent. 
The material was subsequently purified by passing it through 0.45mm nylon syringe filters and 
then through Sephadex G-50 using Milli-Q H2O. The purified material was then passed through 
0.45mm nylon syringe filters and a final column of Sephadex G-50 using Milli-Q H2O to ensure 
purity. Between each column, the material was rotovapped. During collection of the material, 
close attention was paid to the column to ensure only the dark purple/pink materials, which is the 
porphyrin, were collected. After purification, the material was tested for purity using HPLC and 
characterized by UV-vis and 1H-NMR spectroscopy.  
 
RESULTS 
High Performance Liquid Chromatography  
High Performance Liquid Chromatography (HPLC) is a tool used in analytical chemistry 
to determine the purity of a material. It is able to separate, identify, and quantify each component 
in a mixture. Each component within the sample will interact slightly different with the 
stationary phase, causing different elution rates for each component and leading to the separation 
of materials as they elute out of the column. The HPLC instrument uses a pump to pass a 
pressurized liquid and the sample through a column filled with a stationary phase. This leads to 
the separation of components in a mixture. FIGURE 17 and FIGURE 18 show the HPLC results 
for the novel porphyrins. 






Prepared samples were dissolved in Milli-Q H2O and analyzed. H2TPPC-3-PEG-OH 
indicated a 98.8% purity and H2TPPC-3-PiperMe-OH indicated a 99.3% purity. The HPLC 
analysis was completed using a Waters Nova-Pak C18, 3.9 x 150 mm column, with 100% 
acetonitrile at a flow rate of 1.00 mL/min.  
The purity of a material is tested because the development of a pure photosensitizer 
allows higher dosages to be given to patients and decreases the amount of side effects a patient 



















1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
FIGURE 17: 
HPLC results for porphyrin H2TPP-3-PEG-OH. The sample indicated a 98.8% purity.  
FIGURE 18: 
HPLC results for porphyrin H2TPP-3-PiperMe-OH. The sample indicated a 99.3% purity.  
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Characterization of the Porphyrin: UV-Vis Spectroscopy 
Ultraviolet-Visible Spectroscopy (UV-Vis) a tool used in analytical chemistry to 
determine the absorbance a particular sample has. “Molecules containing π-electrons or non-
bonding electrons can absorb energy in the form of ultraviolet or visible light to excite these 
electrons to higher anti-bonding molecular orbitals.” [31] The more easily excited the electrons, 
the longer the wavelength of light it is able to absorb. The instrument functions by allowing a 
beam of light from a visible and/or UV light source, to separate into its component wavelengths 
by a prism or diffraction grating (monochromator). One beam passes through a small transparent 
container, called a cuvette, that contains the sample. The beam’s intensity is measured by 
electronic detectors and are compared to a control sample. The UV region is typically 200 to 350 
nm, while the visible portion is from 350 to 800 nm. Characteristically porphyrins have a strong 
reading at 400 nm, called the “Söret” band, and a series of satellite absorptions from 600 to 800 







 FIGURE 19: 
The UV-vis spectroscopy diagram above shows how light is transmitted through a color filter and 
a monochromator, hits the sample, and data is processed in absorbant amount and wavelengths. 
(https://commons.wikimedia.org/wiki/File:Schematic_of_UV-_visible_spectrophotometer.png) 
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The UV-Vis of both H2TPP-3-PEG-OH and H2TPP-3-PiperMe-OH were obtained. In the 
table below, each porphyrin demonstrates a Söret band at approximately 414 nm, which 
corresponds to a wavelength of maximum absorption, and contained a satellite region with 
appropriate Ɛ values, as shown in FIGURE 20 and FIGURE 21. Accurate sample masses were 




















UV-vis results for porphyrin H2TPP-3-PEG-OH.  
The epsilon values were calculated by  




UV-vis results for porphyrin H2TPP-3-PiperMe-OH. 
The epsilon values were calculated by  
Beer′s Law:  𝐴 = 𝜀𝐶𝑙 
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Characterization of the Porphyrin: NMR Spectroscopy 
Nuclear Magnetic Resonance Spectroscopy (NMR) is a technique used for the 
characterization of organic molecules that contain hydrogen atoms. Every NMR sample is 
prepared in a thin, glass tube (FIGURE 22), or NMR tube. When ready, the sample is placed into 











After comparison of the 1H-NMR of each anime and the final porphyrin product, the 
anime successfully attached to the R group on the porphyrin core structure, as seen in FIGURE 
23 and FIGURE 24.  These results confirmed that the intended porphyrin was produced and 
could proceed to the next step in the research.  
 
FIGURE 22: 
The photo above is of a glass tube used for 1H-NMR. 
 























The results from the 1H-NMR show that that H2TPPC combined with the anime to produce 
the final product, H2TPP-3-PEG-OH. The 1H-NMR for amino-PEG-3-alcohol is on the left, 
while the 1H-NMR for the final porphyrin is on the right. Notice how the peaks are added 
together to make the final product.  
 
FIGURE 24: 
The results from the 1H-NMR show that that H2TPPC combined with the anime to 
produce the final product, H2TPP-3-PiperMe-OH. The 1H-NMR for 3-
piperidinemethanol is on the left, while the 1H-NMR for the final porphyrin is on the 
right. Notice how the peaks are added together to make the final product. 
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MTT ASSAY OF TNBC CELLS 
In many cancer diagnoses, PDT is given to the patient as a treatment option, not as a 
primary choice, but because it is typically the patient’s only option. This is the case for 
individuals diagnosed with MDA-MD-231 triple-negative breast cancer (TNBC). In the United 
States, 1 in 8 women are diagnosed with breast cancer. Those diagnosed with TNBC account for 
nearly 10-15% of all breast cancer cases. Treatment options for TNBC are restricted due to the 
cancer cells not expressing genes for estrogen (ER), progesterone (PR), or human epidermal 
growth factor (HER2) receptors. Cancers with the receptors can be treated with standard cancer 
treatment options, such as chemotherapy. The chemotherapy drug sends a signal to the cancer 
cell to “stop growing”. However, due to the lack of receptors on TNBC cells, a message to “stop 
growing” cannot be transmitted. Individuals diagnosed with TNBC have a high likelihood of 
reoccurrence and an increased risk of dying within five years of diagnosis. PDT is highly 
recommended in cases of TNBC, due to standard cancer treatments having limited effectiveness.  
After characterization, the porphyrins were tested against TNBC cells to determine how 
effective they would be as a treatment option for PDT. To begin, MDA-MD-231 TNBC cells 
were cultured and then plated in 2, 96 well-plates. Approximately 72-hours after plating,  
H2TPP-3-PEG-OH and H2TPP-3-PiperMe-OH were tested in multiple concentrations against the 
TNBC cells. Each treatment was added to 8 replicate wells within the 96 well-plate, with one 
plate designated “dark” and the other “light”. Each plate was wrapped in aluminum foil to 
protect against any light.  
After 18-24 hours of incubation, the cells in the “light” plate were exposed to white light 
(0.5 J/cm2) for approximately 16 minutes. Then, the plate was wrapped in aluminum foil and 
returned to the incubator.  The parallel “dark” plate remained in the incubator. 72 hours post light 
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treatment, cytotoxicity of the porphyrin was measured using an MTT assay and was quantitated 
spectrophotometrically.  
 
MTT Assay Results 
MTT assays are widely used to assess cell viability. [33] The drug MTT-formazan is 
catalyzed by mitochondrial succinate dehydrogenase, meaning the assay is dependent upon 
mitochondrial respiration. This also suggests that it indirectly assesses the cellular energy 
capacity of a cell. The MTT assay indicated that cell viability is greater in cells on the “dark” 
plate compared to those in the “light” plate, which were exposed to light. The cytotoxicity for 
each porphyrin is concentration dependent for both cell environments. The purple formazan 
color indicates living cells.   
One is able to discern from the 96 well-plates in FIGURE 25 and FIGURE 26 below, 
there are two controls and two sections of porphyrin testing. The first row is a positive control, 
containing only TNBC cells and media. The next row is also a positive control, containing 
TNBC cells plus DMSO and media. Then, there are five rows, each with a different 
concentration of the porphyrin, tested in 8 replicate wells. The more viable the cells, the more 
purple the well is. If the well is clear, that indicates no mitochondrial activity, meaning cell 
death. The “dark” plate itself is also a control, as you need to confirm the porphyrin is only 

























Above is a photo the “dark” plate in the MTT assay of TNBC cells for the first 
porphyrin, H2TPP-3-PEG-OH. Notice there are two controls and 5 rows of various 
treatment concentrations, with each concentration in 8 replicate wells.  
 
FIGURE 26: 
Above is a photo the “light” plate in the MTT assay of TNBC cells for the first 
porphyrin, H2TPP-3-PEG-OH. Notice there are two controls and 5 rows of various 
treatment concentrations, with each concentration in 8 replicate wells. At 
concentrations higher than 45 µMol, there is significant cell death.  
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This experiment revealed that at lower concentrations the cells exposed to light have less 
cell viability than those kept in the dark. Shown above, in FIGURE 25 and FIGURE 26, is the 
second MTT Assay trial results for the porphyrin product, H2TPP-3-PEG-OH. It is easy to notice 
that in concentrations higher than 45 µmol, the light treated places show significant cell death. 
Treatment concentrations for H2TPP-3-PEG-OH in the first MTT assay were 1, 3, 10, 30, 100 
µmol and the results are graphed in FIGURE 27. In the second MTT assay, the concentrations 
were changed to 30, 45, 60, 75, 100 µmol to better determine the LD-50 for the porphyrin 
against the TNBC cells. The results are graphed in FIGURE 28.  
The second amine, H2TPP-3-PiperMe-OH is still in testing stages and its results will be 












 FIGURE 27: 
This graph displays the first spectrophotometric MTT assay results for the “light” and 
“dark” plate of porphyrin H2TPP-3-PEG-OH. The concentrations of porphyrin tested 
were 1, 3, 10, 30, and 100 µMol.   
 















With every MTT assay, the goal is to narrow down the LD-50, or the amount of a toxic 
agent (the porphyrin) that is sufficient to kill 50% of a population of animals (TNBC cells) 
usually within a certain time (3 days). The results shown in FIGURE 27 and FIGURE 28 were 
provided by a spectrophotometer, or an instrument that provides a measure of the amount of 
material in the solution absorbing the light. The LD-50 of porphyrin H2TPP-3-PEG-OH was 
slowly being narrowed down, ranging from 25 µmol to 60 µmol. The lower the LD-50 is the 
more toxic the material. This means a lower dosage can be used to treat the patient and therefore, 
decreases the chances of having toxic side-effects.  
 
FIGURE 27: 
This graph displays the second spectrophotometric MTT assay results for the “light” 
and “dark” plate of porphyrin H2TPP-3-PEG-OH. The concentrations of porphyrin 
tested. The concentrations of porphyrin tested were 30, 45, 60, 75, 100 µMol.   
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CONCLUSION   
In conclusion, this research was successful in the creation of two novel, water-soluble 
porphyrins. Each structure, H2TPP-3-PEG-OH and H2TPP-3-PiperMe-OH, was confirmed by 
1H-NMR and HPLC indicated each with high purities of 98.8% and 99.3%, respectively. Both 
also showed characteristics of porphyrins by having the pink or purple coloring in the final 
product and in UV-vis spectroscopy by having a strong Söret band around 414 nm and Q-bands 
from 600 to 800 nm.  
Although results are still pending on H2TPP-3-PiperMe-OH, the H2TPP-3-PEG-OH 
porphyrin appears to kill the TNBC cells when exposed to light in the concentration range 
between 25 µmol to 60 µmol. Under dark conditions, normal growth patterns were seen until the 
porphyrins treatments grew higher in concentration (about 35 µmol). This data indicates that the 
novel porphyrin, H2TPP-3-PEG-OH, may be a viable PDT agent and a possible candidate for the 
treatment against the TNBC cells in mid-to-high concentration ranges. More experimentation 
and trials, however, must be completed to receive more conclusive data.  
 
FUTURE WORK 
 The synthesized novel porphyrins appear to have potential to become PDT agents. In the 
future, further testing will be conducted in an attempt to find each porphyrin’s LD-50, or the 
amount of a toxic agent that is sufficient to kill 50% of a population of animals usually within a 
certain time (3 days), and to establish a trendline for the H2TPP-3-PEG-OH and H2TPP-3-
PiperMe-OH treated cells.  
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Additionally, the porphyrins will be tested to determine if they are viable PDT candidates 
and if the porphyrins have more desirable properties in regard to killing MDA-MD-231 TNBC 
cells.  
 
WHERE IS PDT HEADING? 
 Despite the good the therapy is doing, many areas in PDT pose problems. To realize the 
full potential of PDT, basic physics and engineering issues must be solved. Clinical results could 
be improved remarkably if a direct measurement of light fluorescence distribution during PDT 
was developed and if penetration depth was expanded. Additionally, there could also be 
advancement in light dosimetry, scientists would then have an enhanced understanding of 
tissues’ optical properties, and one could possibly develop a more effective delivery mechanism 
to the treatment site. There are countless opportunities for PDT improvement and many avenues 
in which it might take, including more clinical trials or developing a way to irradiate the entire 
body. [12]  
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KEY WORDS 
Anaplastic Ependymoma – an aggressive form of brain cancer 
Cancer – refers to any one of a large number of diseases characterized by the development of 
abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal 
body tissue. Cancer often has the ability to spread throughout your body. 
Condyloma – (Pl. condylomata) a raised growth on the skin resembling a wart, typically in the 
genital region, caused by viral infection or syphilis and transmissible by contact. 
Ischemia – A clogging of the arteries that can lead to pain, inability to walk, and, in some cases, 
amputation of the leg; an inadequate blood supply to an organ or part of the body, especially the 
heart muscles. 
Leukemia – a malignant progressive disease in which the bone marrow and other blood-forming 
organs produce increased numbers of immature or abnormal leukocytes. These suppress the 
production of normal blood cells, leading to anemia and other symptoms. 
Metastases – the development of secondary malignant growths at a distance from a primary site 
of cancer. 
Onycholysis – a common medical condition characterized by the painless detachment of the nail 
from the nail bed, usually starting at the tip and/or sides. 
Porphyria – a family of metabolic diseases that produce chemicals, called porphyrins, which 
absorb sunlight in the skin and thereby cause damage  
Psoriasis – a common skin condition that speeds up the life cycle of skin cells. It causes cells to 
build up rapidly on the surface of the skin. The extra skin cells form scales and red patches that 
are itchy and sometimes painful. 
Psychosis – a severe mental disorder in which thought, and emotions are so impaired that contact 
is lost with external reality. 
Rickets - is the softening and weakening of bones in children, usually because of an extreme and 
prolonged vitamin D deficiency. 
Slurry – a thin sloppy mud or cement or, in extended use, any fluid mixture of a pulverized solid 
with a liquid (usually water), often used as a convenient way of handling solids in bulk. Slurries 
behave in some ways like thick fluids, flowing under gravity and are also capable of 
being pumped if not too thick. 
Vitiligo – is a disease that causes the loss of skin color in blotches. It occurs when the cells that 
produce melanin die or stop functioning. 
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